18-Methoxycoronaridine (18-MC) is a synthetic derivative of the iboga alkaloid, developed as a potential treatment for drug addiction.
It acts as a nicotinic α3β4 antagonist and has shown efficacy in reducing self-administration of substances like morphine, cocaine, nicotine, and sucrose in animal studies.
Unlike ibogaine, 18-MC does not exhibit significant toxicity or side effects, such as tremors or cerebellar damage. It is currently under investigation in clinical trials for its potential to treat opioid withdrawal and other addictive behaviors.
The compound was first synthesized in 1996 and has since been studied for its anti-addictive properties and safety profile.
The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
Sources:
https://en.wikipedia.org/wiki/18-Methoxycoronaridine
https://pubchem.ncbi.nlm.nih.gov/compound/15479177
https://www.medkoo.com/products/12650
https://www.sciencedirect.com/topics/neuroscience/18-methoxycoronaridine
https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2000.tb05211.x
https://www.eurekaselect.com/article/37148